Download Free Recent Updates On Multiple Myeloma Book in PDF and EPUB Free Download. You can read online Recent Updates On Multiple Myeloma and write the review.

This is a comprehensive, state-of-the-art guide to the diagnosis, treatment, and biology of multiple myeloma and related plasma disorders. Edited and written by a multidisciplinary group of recognized authorities from the Mayo Clinic, it presents clear guidelines on diagnosis and therapy and covers all aspects of multiple myeloma, from molecular classification and diagnosis, to risk stratification and therapy. Closely related plasma cell disorders such as solitary plasmacytoma, Waldenstrom macroglobulinemia, and light chain amyloidosis are discussed in detail as well. The book addresses often overlooked topics, including the role of radiation therapy, vertebral augmentation, and supportive care. Our understanding of this group of disorders is developing at an unprecedented rate, and Multiple Myeloma meets the need among oncologists and hematologists for a clear, timely, and authoritative resource on their biology, diagnosis, and treatment.
This book is a comprehensive overview of the recent developments in the clinical and research fields of multiple myeloma. It is divided into three main sections that cover a wide range of topics, including: epidemiology and pathogenesis of the disease, genetic targets and pathways, resistance to novel therapies, angiogenesis and anti-angiogenesis, hematopoietic stem cell transplantation, role of radiology and radiotherapy in myeloma, infectious complications, and management of multiple myeloma in resource-poor countries.
This book provides a comprehensive overview of multiple myeloma. It is organized into three sections with chapters addressing topics such as diagnosis, risk stratification, and management of multiple myeloma; treatment of multiple myeloma at diagnosis and at relapse; management of disease complications; and stem cell therapies, including autologous and allogeneic hematopoietic stem cell transplantation with a focus on autologous grafting using non-cryopreserved stem cells and performance of stem cell transplantation in outpatient settings.
This book provides a comprehensive overview of multiple myeloma. It is organized into three sections with chapters addressing topics such as diagnosis, risk stratification, and management of multiple myeloma; treatment of multiple myeloma at diagnosis and at relapse; management of disease complications; and stem cell therapies, including autologous and allogeneic hematopoietic stem cell transplantation with a focus on autologous grafting using non-cryopreserved stem cells and performance of stem cell transplantation in outpatient settings.
Since the original publication of Allogeneic Stem Cell Transplantation: Clinical Research and Practice, Allogeneic hematopoietic stem cell transplantation (HSC) has undergone several fast-paced changes. In this second edition, the editors have focused on topics relevant to evolving knowledge in the field in order to better guide clinicians in decision-making and management of their patients, as well as help lead laboratory investigators in new directions emanating from clinical observations. Some of the most respected clinicians and scientists in this discipline have responded to the recent advances in the field by providing state-of-the-art discussions addressing these topics in the second edition. The text covers the scope of human genomic variation, the methods of HLA typing and interpretation of high-resolution HLA results. Comprehensive and up-to-date, Allogeneic Stem Cell Transplantation: Clinical Research and Practice, Second Edition offers concise advice on today's best clinical practice and will be of significant benefit to all clinicians and researchers in allogeneic HSC transplantation.
Multiple myeloma is currently still an incurable disease, but during the past decade knowledge of its molecular pathogenesis has increased rapidly. This has led to remarkable progress in both diagnosis and therapy, including in particular the approval of novel and first-in-class drugs such as thalidomide, bortezomib, and lenalidomide. This book, written by internationally acknowledged experts, covers a wide range of topics relating to multiple myeloma, including history, epidemiology, pathophysiology, clinical features, staging, and prognostic systems. The principal focus, however, is on therapy, with detailed information on the various promising treatment options which give hope that this cancer will be transformed into a chronic disease or even become curable. Individualized therapy and the variety of supportive treatment options, as described in this volume, will help in achieving this goal, as well as in reducing adverse events and improving quality of life.
This handbook is an in-depth and comprehensive guide to the pathophysiology, diagnosis, staging, treatment and management of patients with multiple myeloma. The Handbook was commissioned to address an unmet need for a book of this kind in the myeloma field and to provide busy healthcare professionals with an informative and educational review of the current and emerging treatment recommendations for multiple myeloma. Myeloma is a type of bone marrow cancer arising from plasma cells and is the second most common form of bone marrow cancer, but represents just 1% of all cancers. The causes of myeloma are not fully understood but it is thought to be caused by an interaction of both genetic and environmental factors. This Handbook discusses these issues as well the latest developments in the field and will be an invaluable source of topical information for all healthcare professionals with an interest in multiple myeloma.
This first open access European CAR-T Handbook, co-promoted by the European Society for Blood and Marrow Transplantation (EBMT) and the European Hematology Association (EHA), covers several aspects of CAR-T cell treatments, including the underlying biology, indications, management of side-effects, access and manufacturing issues. This book, written by leading experts in the field to enhance readers’ knowledge and practice skills, provides an unparalleled overview of the CAR-T cell technology and its application in clinical care, to enhance readers’ knowledge and practice skills.
This book is a comprehensive overview of the recent developments in the clinical and research fields of multiple myeloma. It is divided into three main sections that cover a wide range of topics, including: epidemiology and pathogenesis of the disease, genetic targets and pathways, resistance to novel therapies, angiogenesis and anti-angiogenesis, hematopoietic stem cell transplantation, role of radiology and radiotherapy in myeloma, infectious complications, and management of multiple myeloma in resource-poor countries.
This book "Contemporary Management of Multiple Myeloma" discusses in detail about the management of multiple myeloma. Multiple Myeloma is the second most common hematological malignancy in the United States. This book highlights the interplay between the malignant plasma cell and the microenvironment, and the role of genetic alterations, adhesion molecules and critical cytokines in this complex milieu. The first chapter of this book discusses epidemiology, etiology and pathogenesis of multiple myeloma. The clinical presentation of the common plasma cell dyscrasias and discuss the diagnostic and prognostic work-up with a highlighting on recent advances in chapters 3 and 4. Chapters from 5 to 9 focus on the therapeutic evolution that has occurred, and accumulate the landmark clinical trials that have changed clinical practice for up-front treatment of both transplant eligible and ineligible patients and for those with relapsed and refractory disease. These chapters also highlights on the important role of clinical research with stem cell transplantation, proteasome-inhibition and immunomodulatory drugs that form the backbone of our present day therapeutic armamentarium. Recommendations for response assessment and current understanding of the value of maximizing the depth of response in personalized therapy and patient segmentation are briefly explained in chapters 10 and 11. Chapter 12 and 13 discussed about adjunctive treatment modalities and novel therapeutic compounds in clinical trial and targets for future drug development. This book provides complete information about current landscape for multiple myeloma which is helpful in future aspects.